

PREVALENCE OF GERD

Defined by Symptoms

- Up to 40% of adults
- 50% of GERD patients have complicated disease
- Chronic disease in most

Erosive GERD

Presentations in Practice

Esophageal –Typical Symptoms

- **Heartburn (nighttime/daytime)**
- **Extraesophageal regurgitation**


Extraesophageal – Atypical Symptoms

- **Dysphagia**
- **Bleeding (including occult)**
- **Noncardiac chest pains**
- **Hoarseness**
- **Cough, wheezing**
- **Asthma-like symptoms**

Untreated Complications

- **Peptic stricture**
- **Barrett's esophagus**
- **Esophageal adenocarcinoma**

Pathophysiology of GERD



Gastroesophageal Reflux

Damage correlates with duration of reflux
exposure

AND

Caustic potential of refluxed material

Mechanism of Reflux

- Transient decrease in LES with normal baseline
 - Truly hypotensive sphincter
 - Hiatal hernia

Protection from Reflux

- Protection from reflux afforded by esophageal acid clearance

Prolongation of clearance time occurs in 50% of GERD patients

THE GERD SPECTRUM

**Typical
Manifestations
(Heartburn/Regurgitation)**

**With Erosive Esophagitis
Without Esophagitis***

**Atypical
Manifestations***

**Angina-like Pain
Asthma/Cough
Laryngitis**

Complications


**Ulceration
Stricture
Metaplasia
(Barrett's)**

*** Requires Abnormal pH-metry**

Clinical Manifestations

- Heartburn
- Regurgitation
- Chronic Coughing

Impact of heartburn during sleep



Role of Endoscopy

Alarm symptoms

Dysphagia

Odynophagia


Bleeding

Chest pain


Supraesophageal symptoms

Use of Medication for Heartburn


(n = 1,000)




Healing of Erosive Esophagitis




Relief of Heartburn





PPI v. H2RA in Maintaining Remission




Healing of Erosive GERD









Nocturnal Acid Breakthrough



NAB in GERD



Nonerosive Reflux Disease



NERD v. EE

Heartburn severity is similar

Response to Rx is 10–30% less

Rarely have typical complications but rather atypical complications/symptoms

24 hr esophageal pH studies normal in 50%

Heartburn and Normal Endoscopy

- Abnormal acid exposure
- Functional heartburn
- Hypersensitive v. not acid reflux

GERD and the OLDER Patient

- Frequency
- Factors that influence
 - LES pressures
 - Acid clearing time
 - Hiatal hernia

WARNING

- Older patient less likely to report heartburn
- More likely to have dysphagia, chest pain, or vomiting

Severity of symptoms does not correlate with the degree of esophagitis therefore lower threshold to do endoscopy

Barrett's Esophagus

- Columnar epithelium replaces the squamous epithelium in the distal esophagus when reflux disease damages the mucosa and healing occurs through a metaplastic process. This columnar epithelium is a form of intestinal metaplasia that is prone to develop adenocarcinoma.

Treatment

- Symptom Relief
 - PPIs
 - Complications
 - Erosions, ulcers, strictures
 - Progression of metaplasia
- Effective acid suppression one step forward
 - Mucosal ablation may be key

Treatment of Reflux in Barrett's

■ Rationale

Exposure to esophageal acid activates protein kinase pathways that increase proliferation and decrease apoptosis.

Markers of proliferation were reduced in esophageal biopsies when acid was normalized by PPI.

? Screen GERD for Barrett's ?

■ EGD in GERD

- 3 to 5% have long segment

- 10 to 15% have short segment

■ Who to screen ?

- White males > 50 with Gerd > 5 yrs.

Dysplasia

- HGD associated with cancer 30-40%
- ACG Recommendation
 - No dysplasia q 3 yr
 - Low grade q 6 mo. x 2
 - No progression then q 1 yr.

Surveillance

- Treat aggressively prior to bx's
 - HGD get 2nd opinion
- Surgery v. survey q 3 mo.

Surveillance Initial Dx

patients	19	58
stage 0-1	58 %	17 %
5-yr. survival	62 %	20 %

Barrett's and Surgery

- 10 studies with 408 patients
 - 86% Segment unchanged
- Equal numbers regressed/progressed

Mucosal Ablation

Photodynamic therapy (PDT)

100 patients

Barrett's undetectable in 43


Eradication HGD 88%

Eradication LGD 92%

Ablative Therapy

Endoscopic mucosal resection
(EMR)

Protonix 40 mg I.V. vs. Placebo



*pentagastrin stimulated

Data on file, Wyeth-Ayerst Laboratories. Study 100-US.
Pisegna JR et al. *Am J Gastroenterol.* 1999;94:2874-2880.